Biopharmaceutical Manufacturing, Upstream, Downstream processing news

Top Headlines

Gilead/Kite's Yescarta becomes the second CAR T therapy to be approved in the US. GettyImages/Yescarta

Gilead ramping up CAR T clinics after US FDA Yescarta approval

Gilead says it is looking to make as many as 90 academic centres available to administer CAR-T Yescarta (axicabtagene ciloleucel) following its approval in the US.

Univercells: 'Micro-facilities' to slash the cost of vaccine manufacture

High-density single-use bioreactors, small facilities and continuous manufacturing will cut the cost of manufacturing polio vaccines down to $0.15 per dose, says Univercells.

HPRA raises Brexit concerns: GMP mutual recognition & member state status

Irish regulators say it is still not clear how Brexit will affect companies that make drugs in the UK, raising issues like MA status and mutual inspection agreements between the EMA and US FDA as areas of concern.

Ex-Hurricane Ophelia & Ireland-based manufacturing: Pfizer, Roche & Takeda update

Storm Ophelia hit the Green Isle this week, forcing the closure of schools, public institutions, and a number of drug manufacturing sites across the country.

GSK taps Plasticell's stem cell differentiation tech

GSK will look to optimise its induced pluripotent stem cell (iPSC) differentiation processes through collaboration with high throughput tech firm Plasticell.

'Luxturna' recommendation good for all AAV based gene therapies says advocacy group

The US approval recommendation for Spark Therapeutics’ blindness gene therapy voretigene neparvovec is also an endorsement of AAV delivery technologies according to the Alliance for Regenerative Medicine.